近几年发现某些化疗药物在低剂量、长时间接触中可选择性抑制血管内皮细胞的功能,且不受肿瘤细胞耐药状态的影响,与传统的最大耐受量化疗不同,主要是剂量低,间歇期短,能持续应用。本文对节律性化疗在血液病患者中的应用、作用机制、优势及其与其他治疗方法结合等方面的现状和前景进行综述。%In recent years,we found that certain chemotherapy drugs in low dose and prolonged exposure could selec-tively inhibit vascular endothelial cell function,and not subject to the state of drug - resistant tumor cells,differ from conventional chemotherapy of the maximum tolerated dose mainly in low dose,short intermittent duration,and continu-ance to apply. In this essay,we reviewed the status quo and prospects of rhythmic chemotherapy in the application, mechanism,advantages and their combination with other treatment methods in patients of hematonosis.
展开▼
机译:随机,安慰剂对照,FosapRepitant,Ondansetron,Dexamethasone(喜欢的)与Fond Plus Olanzapine(FONE-O)进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐,ondansetron,ondansetron(Fond-O)的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者 方案:FOND-O试验
机译:随机,安慰剂对照,FosapRepitant,Ondansetron,Dexamethasone(喜欢的)与Fond Plus Olanzapine(FONE-O)进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐,ondansetron,ondansetron(Fond-O)的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者方案:FOND-O试验